GlassScriptPhysician profile
Michelle T Snyder
NPI 1073008298
$1,263.44
in general payments reported to CMS, 2019-2025
19 companies · $240 in 2025
The $240 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $511 · 2023: $178 · 2024: $334 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $190.53 | 2022 | |
| Corium, LLC | $165.70 | 2022-2025 | Azstarys |
| Revance Therapeutics, INC. | $145.78 | 2024 | Daxi |
| Ironshore Pharmaceuticals INC. | $120.52 | 2022-2023 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $98.49 | 2024-2025 | |
| Pfizer INC. | $87.61 | 2022-2025 | |
| Phadia US INC. | $69.39 | 2022-2024 | Immunocap |
| Alk-Abello, INC | $58.72 | 2025 | Neffy, Odactra, Grastek |
| Cranial Technologies, INC | $53.39 | 2023-2025 | Doc Band |
| Apellis Pharmaceuticals, INC. | $43.55 | 2024-2025 | Syfovre |
| Supernus Pharmaceuticals, INC. | $40.74 | 2024 | Qelbree |
| Seqirus USA INC | $36.58 | 2022 | |
| Glaxosmithkline, LLC. | $31.67 | 2025 | Bexsero |
| Galderma Laboratories, L.P. | $29.52 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $25.82 | 2022-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.00 | 2023 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $17.94 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.36 | 2025 | Jornay Pm |
| Kaleo, INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.